Remove en products meetings
article thumbnail

Parallel import of medicinal products: regulatory update

European Pharmaceutical Review

Parallel import of medicinal products is one of the basic and admissible forms of international trade in the European Union (EU) market, based on the principle of free movement of goods established by the Treaty on the Functioning of the European Union.

article thumbnail

Vaccines upstart Curevo has designs on blockbuster GSK franchise

pharmaphorum

That heavyweight competition could pose a big challenge to Curevo, which says CRV-101 has the potential to have a better safety profile, production yields and “equivalent effectiveness” to Shingrix, which GSK has predicted will become a $6 billion product at peak.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DBV craters on FDA’s peanut allergy immunotherapy rejection

pharmaphorum

The agency is asking for a new “human factor study” to examine how well the patch-based product adhere to the skin, and how that affects efficacy, according to DBV. DBV says it plans to request a meeting with the FDA to discuss its comments in the CRL as well, as that may be needed in another clinical trial to support another refiling. “We

FDA 52
article thumbnail

2021 market access prospects for Spain

pharmaphorum

The health economic component of the revamped IPTs is informed by guidelines from the Grupo de Evaluación de Novedades, EStandarización e Investigación en Selección de Medicamentos (Group for the Evaluation of Innovations, Standardisation and Research in Drug Selection, GENESIS).

article thumbnail

Microbiome therapies: a maturing movement

European Pharmaceutical Review

Riding on the momentum of the first faecal microbiota product approved for C. At MaaT Pharma our donor-derived products are made through pooling (ie, mixing multiple donors), thus achieving a higher overall richness and standardisation of the resulting drug product. coli strains in the gut”.

article thumbnail

Regeneron’s cholesterol drug evinacumab claims February FDA date

pharmaphorum

Evinacumab is expected to be a smaller product, thanks to the tiny population affected by the ultra-rare indication, although Regeneron will be able to detail using the same salesforce that sells Praluent, reducing the cost of rollout if approved. The post Regeneron’s cholesterol drug evinacumab claims February FDA date appeared first on.

FDA 52
article thumbnail

2023 ISPE Aseptic Conference Regulatory Panel

ISPE

At this year’s session, most questions focused on technical pharmaceutical queries related to sterile products, whereas last year’s panel had a lot of questions around audit practices during the pandemic and learnings from virtual and hybrid inspections. Attendees were invited to submit questions to the FDA representatives.

FDA 52